|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
adults
children
|
|
gptkbp:approvedBy
|
1995
|
|
gptkbp:ATCCode
|
gptkb:J07BK01
|
|
gptkbp:brand
|
gptkb:Varilrix
gptkb:Varivax
|
|
gptkbp:broadcastOn
|
two doses
|
|
gptkbp:contains
|
live attenuated varicella-zoster virus
|
|
gptkbp:contraindication
|
pregnancy
immunocompromised individuals
|
|
gptkbp:countryOfOrigin
|
gptkb:Japan
|
|
gptkbp:developedBy
|
gptkb:Michiaki_Takahashi
|
|
gptkbp:effect
|
over 90% after two doses
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
varicella vaccine
|
|
gptkbp:includedIn
|
childhood immunization schedule
|
|
gptkbp:notRecommendedFor
|
severe allergic reaction to vaccine component
|
|
gptkbp:prevention
|
gptkb:chickenpox
|
|
gptkbp:recommendation
|
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:World_Health_Organization
|
|
gptkbp:reduces
|
gptkb:herpes_zoster_(shingles)
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
fever
injection site reaction
mild rash
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Chickenpox
gptkb:Varicella
|
|
gptkbp:bfsLayer
|
5
|